Avadel Pharmaceuticals plc

DB:AWK Stock Report

Market Cap: €952.2m

Avadel Pharmaceuticals Management

Management criteria checks 3/4

Avadel Pharmaceuticals' CEO is Greg Divis, appointed in Jan 2019, has a tenure of 5.92 years. total yearly compensation is $985.20K, comprised of 60.9% salary and 39.1% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth €1.67M. The average tenure of the management team and the board of directors is 5 years and 6.4 years respectively.

Key information

Greg Divis

Chief executive officer

US$985.2k

Total compensation

CEO salary percentage60.9%
CEO tenure5.9yrs
CEO ownership0.2%
Management average tenure5yrs
Board average tenure6.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Greg Divis's remuneration changed compared to Avadel Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$73m

Jun 30 2024n/an/a

-US$106m

Mar 31 2024n/an/a

-US$157m

Dec 31 2023US$985kUS$600k

-US$160m

Sep 30 2023n/an/a

-US$159m

Jun 30 2023n/an/a

-US$143m

Mar 31 2023n/an/a

-US$142m

Dec 31 2022US$754kUS$561k

-US$137m

Sep 30 2022n/an/a

-US$132m

Jun 30 2022n/an/a

-US$134m

Mar 31 2022n/an/a

-US$90m

Dec 31 2021US$3mUS$545k

-US$77m

Sep 30 2021n/an/a

-US$66m

Jun 30 2021n/an/a

-US$56m

Mar 31 2021n/an/a

-US$6m

Dec 31 2020US$3mUS$520k

US$7m

Sep 30 2020n/an/a

US$16m

Jun 30 2020n/an/a

US$18m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$1mUS$472k

-US$33m

Sep 30 2019n/an/a

-US$94m

Jun 30 2019n/an/a

-US$101m

Mar 31 2019n/an/a

-US$96m

Dec 31 2018US$685kUS$417k

-US$95m

Sep 30 2018n/an/a

-US$40m

Jun 30 2018n/an/a

-US$2m

Mar 31 2018n/an/a

US$30m

Dec 31 2017US$1mUS$375k

US$68m

Compensation vs Market: Greg's total compensation ($USD985.20K) is below average for companies of similar size in the German market ($USD1.46M).

Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.

CEO

Greg Divis (57 yo)

5.9yrs

Tenure

US$985,200

Compensation

Mr. Gregory J. Divis Jr., also known as Greg, has been Director of Avadel Pharmaceuticals plc since June 3, 2019 and has been its Chief Executive Officer since January 2019. Mr. Divis served as an Interim...

Leadership Team

NamePositionTenureCompensationOwnership
Gregory Divis
CEO & Director5.9yrsUS$985.20k0.18%
€ 1.7m
Thomas McHugh
Senior VP5yrsUS$663.14k0.091%
€ 867.6k
Richard Kim
Chief Commercial Officer3.8yrsUS$770.95k0%
€ 0
Jerad Seurer
General Counsel & Company Secretary4.3yrsno data0.0091%
€ 86.9k
Gregory Davis
VP of Corporate and Business Development9.4yrsno data0.17%
€ 1.6m
Mark Elrod
Vice President of Sales8.3yrsno datano data
Angie Woods
Vice President of People & Culture3.6yrsno datano data
Jordan Dubow
Consultant5.7yrsUS$982.54kno data
Jason Vaughn
Senior Vice President of Technical Operations5yrsno datano data
Jennifer Gudeman
Senior Vice President of Medical & Clinical Affairsno datano datano data

5.0yrs

Average Tenure

56yo

Average Age

Experienced Management: AWK's management team is seasoned and experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gregory Divis
CEO & Director5.5yrsUS$985.20k0.18%
€ 1.7m
Jean-Marie Lehn
Member of Scientific Advisory Board19.9yrsno datano data
Mark McCamish
Independent Director5yrsUS$449.84k0.070%
€ 662.3k
Naseem Amin
Independent Directorless than a yearno datano data
Peter Thornton
Independent Director7.5yrsUS$459.84k0.086%
€ 820.7k
Christian Trepo
Member of Scientific Advisory Board19.9yrsno datano data
Patrick Couvreur
Member of Scientific Advisory Boardno datano datano data
Eric Ende
Independent Director6yrsUS$452.34k0.17%
€ 1.7m
Catherine Bréchignac
Chairman of Scientific Advisory Boardno datano datano data
Geoffrey Glass
Independent Non-Executive Chairman of the Board6.4yrsUS$482.34k0.15%
€ 1.4m
Linda Palczuk
Independent Director6.4yrsUS$452.34k0.057%
€ 547.4k

6.4yrs

Average Tenure

62yo

Average Age

Experienced Board: AWK's board of directors are considered experienced (6.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:19
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Avadel Pharmaceuticals plc is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robin Garner KalleyCraig-Hallum Capital Group LLC
Chase KnickerbockerCraig-Hallum Capital Group LLC
Oren LivnatH.C. Wainwright & Co.